Oral laquinimod for treatment of relapsing-remitting multiple sclerosis

The Lancet Neurology

Volumn 7, Issue 8, 2008, Pages 672-673

  Weiner, Howard L ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BETA INTERFERON; CLADRIBINE; FINGOLIMOD; FUMARIC ACID DIMETHYL ESTER; GADOLINIUM; GLATIRAMER; LAQUINIMOD; NATALIZUMAB; TERIFLUNOMIDE;

ANTIINFLAMMATORY ACTIVITY; CLINICAL TRIAL; DISEASE COURSE; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; HUMAN; LETTER; LEUKOENCEPHALOPATHY; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PRIORITY JOURNAL; RELAPSE; THROMBOCYTOPENIC PURPURA; UNSPECIFIED SIDE EFFECT; VIRUS INFECTION;

ADMINISTRATION, ORAL; HUMANS; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; QUINOLONES;

EID: 46849119589     PISSN: 14744422     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1474-4422(08)70148-0     Document Type: Letter

References (6)

1. Comi G., Pulizzi A., Rovaris M., et al. Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet 371 (2008) 2085-2092
2. Brunmark C., Runström A., Ohlsson L., et al. The new orally active immunoregulator laquinimod (ABR-215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitis. J Neuroimmunol 130 (2002) 163-172
3. Polman C., Barkhof F., Sandberg-Wollheim M., et al. Treatment with laquinimod reduces development of active MRI lesions in relapsing MS. Neurology 64 (2005) 987-991
4. Kappos L., Bates D., Hartung H., et al. Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring. Lancet Neurol 6 (2007) 431-441
5. Kappos L., Antel J., Comi G., et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med 355 (2006) 1124-1140
6. Coles A. Alemtuzumab improved multiple sclerosis functional composite scores and delayed time to first relapse at 2-year interim analysis compared to subcutaneous interferon beta-1a. Mult Scler 13 (2007) S166 (abstract).